Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-101 phase 2a trial in primary sclerosing cholangitis
2019-002945-39Phase 2Unknown
- Sponsor
- Chemomab Therapeutics
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing CM-101 with Placebo (2 arms). Primary endpoints: Change from baseline through Week 15 in serum alkaline phosphatase levels by treatment cohort and Reduction in ELF score. Status: unknown.
02
Drugs
nebokitug
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2019-002945-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002945-39.